Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Aceclidine Hydrochloride
Therapeutic Area : Ophthalmology
Study Phase : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
CORXEL And LENZ Report Phase 3 Data for Presbyopia Drug LNZ100
Details : LNZ100 is a preservative-free, single-use, once-daily eye drop containing aceclidine, being developed for the treatment of presbyopia.
Brand Name : LNZ100
Molecule Type : Small molecule
Upfront Cash : Not Applicable
October 27, 2024
Lead Product(s) : Aceclidine Hydrochloride
Therapeutic Area : Ophthalmology
Highest Development Status : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Aceclidine Hydrochloride
Therapeutic Area : Ophthalmology
Study Phase : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
LENZ Gets FDA Acceptance for LNZ100 NDA for Presbyopia Treatment
Details : LNZ100 is a preservative-free, single-use, once-daily eye drop containing aceclidine, being developed for the treatment of presbyopia.
Brand Name : LNZ100
Molecule Type : Small molecule
Upfront Cash : Not Applicable
October 21, 2024
Lead Product(s) : Aceclidine Hydrochloride
Therapeutic Area : Ophthalmology
Highest Development Status : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Aceclidine Hydrochloride
Therapeutic Area : Ophthalmology
Study Phase : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
LENZ Submits NDA to FDA for LNZ100 to Treat Presbyopia
Details : LNZ100 is a preservative-free, single-use, once-daily eye drop containing aceclidine, being developed for the treatment of presbyopia.
Brand Name : LNZ100
Molecule Type : Small molecule
Upfront Cash : Not Applicable
August 12, 2024
Lead Product(s) : Aceclidine Hydrochloride
Therapeutic Area : Ophthalmology
Highest Development Status : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Aceclidine Hydrochloride,Brimonidine Tartrate
Therapeutic Area : Ophthalmology
Study Phase : Phase III
Sponsor : Ridgeback Capital
Deal Size : $30.0 million
Deal Type : Private Placement
LENZ Therapeutics Announces $30 Million Investment from Ridgeback Capital
Details : The net proceeds will be used to fund the clinical advancement of LNZ100 (aceclidine & brimonidine tartrate), which is being evaluated in the late-stage clinical trial for the treatment of Presbyopia.
Brand Name : LNZ100
Molecule Type :
Upfront Cash : Undisclosed
July 15, 2024
Lead Product(s) : Aceclidine Hydrochloride,Brimonidine Tartrate
Therapeutic Area : Ophthalmology
Highest Development Status : Phase III
Sponsor : Ridgeback Capital
Deal Size : $30.0 million
Deal Type : Private Placement
Lead Product(s) : Aceclidine Hydrochloride,Brimonidine Tartrate
Therapeutic Area : Ophthalmology
Study Phase : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
LENZ Therapeutics Announces Positive Topline Data from Phase 3 CLARITY Presbyopia Trials
Details : LNZ101 is a fixed dose opthalmic solution of aceclidine (mAChRs agonist) & brimonidine (ADRA2 agonist), which is being evaluated for the treatment of presbyopia.
Brand Name : LNZ101
Molecule Type : Small molecule
Upfront Cash : Not Applicable
April 03, 2024
Lead Product(s) : Aceclidine Hydrochloride,Brimonidine Tartrate
Therapeutic Area : Ophthalmology
Highest Development Status : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Aceclidine Hydrochloride,Brimonidine Tartrate
Therapeutic Area : Ophthalmology
Study Phase : Phase III
Sponsor : Versant Ventures
Deal Size : $53.5 million
Deal Type : Private Placement
LENZ Completes Merger with Graphite Bio and Updates On Progress
Details : The net proceeds will advance LENZ’s lead programs, LNZ100 and LNZ101, preservative-free, single-use, once-daily eye drops for treating presbyopia.
Brand Name : LNZ101
Molecule Type : Small molecule
Upfront Cash : Undisclosed
March 21, 2024
Lead Product(s) : Aceclidine Hydrochloride,Brimonidine Tartrate
Therapeutic Area : Ophthalmology
Highest Development Status : Phase III
Sponsor : Versant Ventures
Deal Size : $53.5 million
Deal Type : Private Placement
Lead Product(s) : Aceclidine Hydrochloride,Brimonidine Tartrate
Therapeutic Area : Ophthalmology
Study Phase : Phase III
Sponsor : Graphite Bio
Deal Size : Undisclosed
Deal Type : Merger
LENZ Completes Merger with Graphite Bio and Provides Clinical and Corporate Update
Details : The collaboration will advance LENZ’s lead programs, LNZ100 and LNZ101, preservative-free eye drops containing aceclidine and aceclidine plus brimonidine for presbyopia treatment.
Brand Name : LNZ101
Molecule Type : Small molecule
Upfront Cash : Undisclosed
March 21, 2024
Lead Product(s) : Aceclidine Hydrochloride,Brimonidine Tartrate
Therapeutic Area : Ophthalmology
Highest Development Status : Phase III
Sponsor : Graphite Bio
Deal Size : Undisclosed
Deal Type : Merger
Lead Product(s) : Aceclidine Hydrochloride,Brimonidine Tartrate
Therapeutic Area : Ophthalmology
Study Phase : Phase III
Sponsor : LENZ Therapeutics
Deal Size : Undisclosed
Deal Type : Merger
LENZ Therapeutics and Graphite Bio Announce Merger Agreement
Details : The combined will focus on the advancement of LENZ’s lead programs, LNZ100 and LNZ101, which are preservative-free, single-use, once-daily eye drops containing aceclidine and aceclidine plus brimonidine, respectively, for the treatment of presbyopia.
Brand Name : LNZ101
Molecule Type : Small molecule
Upfront Cash : Undisclosed
November 15, 2023
Lead Product(s) : Aceclidine Hydrochloride,Brimonidine Tartrate
Therapeutic Area : Ophthalmology
Highest Development Status : Phase III
Sponsor : LENZ Therapeutics
Deal Size : Undisclosed
Deal Type : Merger
Lead Product(s) : Aceclidine Hydrochloride,Brimonidine Tartrate
Therapeutic Area : Ophthalmology
Study Phase : Phase III
Sponsor : Versant Ventures
Deal Size : $53.5 million
Deal Type : Private Placement
LENZ Therapeutics and Graphite Bio Announce Merger Agreement
Details : The net proceeds will be used on the advancement of LENZ’s lead programs, LNZ100 and LNZ101, which are preservative-free, single-use, once-daily eye drops containing aceclidine and aceclidine plus brimonidine, respectively, for the treatment of presbyo...
Brand Name : LNZ101
Molecule Type : Small molecule
Upfront Cash : Undisclosed
November 15, 2023
Lead Product(s) : Aceclidine Hydrochloride,Brimonidine Tartrate
Therapeutic Area : Ophthalmology
Highest Development Status : Phase III
Sponsor : Versant Ventures
Deal Size : $53.5 million
Deal Type : Private Placement
Lead Product(s) : Aceclidine Hydrochloride,Brimonidine Tartrate
Therapeutic Area : Ophthalmology
Study Phase : Phase III
Sponsor : Sectoral Asset Management
Deal Size : $83.5 million
Deal Type : Series B Financing
Details : The Proceeds will enable LENZ to complete the development and registration and, pending approval, launch LNZ100 (aceclidine) and LNZ101 (aceclidine and brimonidine) in the United States.
Brand Name : LNZ101
Molecule Type : Small molecule
Upfront Cash : Undisclosed
March 07, 2023
Lead Product(s) : Aceclidine Hydrochloride,Brimonidine Tartrate
Therapeutic Area : Ophthalmology
Highest Development Status : Phase III
Sponsor : Sectoral Asset Management
Deal Size : $83.5 million
Deal Type : Series B Financing
LOOKING FOR A SUPPLIER?